2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: ...

iShares Biotechnology ETF (IBB) offers targeted exposure to the U.S. biotechnology sector, providing investors with access to ...

Intellia Therapeutics also has fans on Wall Street. The company's current average price target of $32.3 (according to Yahoo!

Federal regulators are trying to make it easier to develop cheaper alternatives to powerful drugs that many Americans depend ...

Edesa Biotech has announced positive results from a Phase III clinical trial of its drug candidate, paridiprubart (EB05), for ...

The U.S. Food and Drug Administration is preparing to accelerate approvals for biosimilars, or generic versions of complex ...

For Novo, it marks the boldest move yet for recently appointed CEO Maziar Mike Doustdar. In response to a slowdown in sales ...

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

Embargoed for 9am CET (3am ET) on Monday November 3rdAmgen Ventures-backed AAVantgarde Bio has raised $143 million in series ...

Q VYJUVEK revenue and $623.2 million since U.S. launch VYJUVEK launched in Germany in 3Q; launched in France and Japan in ...

The upcoming EU Biotech Act may be more prominently focused on health. But it will also significantly impact food and food ...